Literature DB >> 22325999

Morton's neuroma: A clinical versus radiological diagnosis.

Philip Pastides1, Sameh El-Sallakh, Charalambos Charalambides.   

Abstract

BACKGROUND: The aim of our study was to compare the clinical versus radiological diagnosis of patients suffering from a Morton's neuroma.
METHODS: Clinical assessments and pre-operative radiological imaging of patients who had excision of a Morton's neuromas were retrospectively compared.
RESULTS: 43 neuromas were excised from 36 patients over 68 months. The commonest clinical symptoms were tenderness on direct palpation (100%), pain on weight bearing (91%) which was relieved by rest (81%). The most sensitive clinical sign was a Mulder's click. Clinical assessment had a sensitivity of 98% (42/43). Ultrasonography had a sensitivity of 90% (28/31) and magnetic resonance imaging had a sensitivity of 88% (14/16).
CONCLUSION: There is no absolute requirement for imaging patients who clinically have a Morton's neuroma. The two main indications for imaging are (a) an unclear clinical assessment and (b) cases when more than one web space is affected. Ultrasonography should be the investigation of choice.
Copyright © 2011 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22325999     DOI: 10.1016/j.fas.2011.01.007

Source DB:  PubMed          Journal:  Foot Ankle Surg        ISSN: 1268-7731            Impact factor:   2.705


  8 in total

1.  Short term comparison between blind and ultrasound guided injection in morton neuroma.

Authors:  Fernando Ruiz Santiago; Nicolás Prados Olleta; Pablo Tomás Muñoz; Luis Guzmán Álvarez; Alberto Martínez Martínez
Journal:  Eur Radiol       Date:  2018-07-31       Impact factor: 5.315

Review 2.  Ultrasound versus magnetic resonance imaging for Morton neuroma: systematic review and meta-analysis.

Authors:  Bianca Bignotti; Alessio Signori; Maria Pia Sormani; Luigi Molfetta; Carlo Martinoli; Alberto Tagliafico
Journal:  Eur Radiol       Date:  2015-03-26       Impact factor: 5.315

3.  Regenerative surgery of the complications with Morton's neuroma surgery: use of platelet rich plasma and hyaluronic acid.

Authors:  Barbara De Angelis; Lucilla Lucarini; Fabrizio Orlandi; Annarita Agovino; Alessia Migner; Valerio Cervelli; Valentina Izzo; Cristiano Curcio
Journal:  Int Wound J       Date:  2012-06-14       Impact factor: 3.315

4.  Treatment of Morton's neuroma with minimally invasive distal metatarsal metaphyseal osteotomy (DMMO) and percutaneous release of the deep transverse metatarsal ligament (DTML): a case series with minimum two-year follow-up.

Authors:  Gustavo Sato; Gabriel Ferraz Ferreira; Davy Sevilla; Carolinne Nascimento Oliveira; Thomas Lorchan Lewis; Mauro Cesar Mattos E Dinato; Miguel Viana Pereira Filho
Journal:  Int Orthop       Date:  2022-08-29       Impact factor: 3.479

5.  Percutaneous alcohol injection under sonographic guidance in Morton's neuroma: follow-up in 220 treated lesions.

Authors:  Luciano Perini; Claudia Perini; Matteo Tagliapietra; Davide Varotto; Andrea Valcarenghi; Andrea Postorino; Antonio Volpe
Journal:  Radiol Med       Date:  2016-02-16       Impact factor: 3.469

Review 6.  The accuracy of diagnostic ultrasound imaging for musculoskeletal soft tissue pathology of the extremities: a comprehensive review of the literature.

Authors:  Rogan E A Henderson; Bruce F Walker; Kenneth J Young
Journal:  Chiropr Man Therap       Date:  2015-11-05

7.  Intense focused ultrasound preferentially stimulates subcutaneous and focal neuropathic tissue: preliminary results.

Authors:  Abbi M McClintic; Trevor C Dickey; Michael Gofeld; Michel Kliot; John D Loeser; Philippe Richebe; Pierre D Mourad
Journal:  Pain Med       Date:  2012-11-08       Impact factor: 3.750

8.  The clinical diagnosis of symptomatic forefoot neuroma in the general population: a Delphi consensus study.

Authors:  Charlotte Dando; Lindsey Cherry; Lyndon Jones; Catherine Bowen
Journal:  J Foot Ankle Res       Date:  2017-12-28       Impact factor: 2.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.